BPC-157 + TB-500 10mg — Tissue Regeneration Research Combo

Zoom

59,00 €

Tax included • Free delivery from 99€

+2,95 € in loyalty cashback, with an account. Create my account

16 in stock · Ships from France

Next dispatch: Tuesday, September 8

Subscription

53,10 €-10 %instead of 59,00 €

-10 % for life on each cyclePause, skip or cancel in 1 clickNo commitment, no hidden fees

What the parcel contains

One sealed vial of BPC-157 + TB-500 10mg, lyophilised, without individual labelling.

What you also need

Bacteriostatic water for reconstitution and 1 ml precision syringes graduated in 100 units, sold separately. The vial alone cannot be used as is.

Don't forget the essentials

Eau Bactériostatique

7,90 €

The BPC-157 + TB-500 10mg combo delivers in a single vial the two most extensively studied tissue regeneration peptides in musculoskeletal research: 5 mg of BPC-157 (Body Protection Compound-157, a 15-amino-acid pentadecapeptide derived from human gastric juice, isolated by Predrag Sikiric's team at Zagreb from the 1990s) paired with 5 mg of TB-500 (active fragment of thymosin beta-4 described by Allan Goldstein in 1981, 44-residue ubiquitous regeneration peptide). Together these molecules constitute the reference pairing in tendon, ligament, muscle and vascular repair research: two complementary mechanisms of action, one shared angiogenic vector, and dramatically expanded tissue coverage.

BPC-157 operates locally as an ultra-stable cytoprotectant: it survives gastric milieu, reactivates the VEGF-receptor-2 pathway at the lesion site, modulates the nitric oxide system (NO / eNOS), upregulates growth hormone receptors on tendon fibroblasts (Chang et al. 2011), and orchestrates the FAK-paxillin signaling cascade governing cell migration within tendon tissue. TB-500 operates systemically as a cytoskeleton remodeler: its primary function is G-actin monomer sequestration (active N-terminal Ac-Ser-Asp-Lys-Pro), its cleaved AcSDKP sequence is an autonomous angiogenic factor, it upregulates laminin-5 and matrix metalloproteinases (MMPs), and mobilizes mesenchymal progenitor cells.

The value of the combo lies in mechanistic divergence coupled with vascular convergence: BPC-157 covers local cytoprotection and the gut-tendon axis, TB-500 covers systemic cell migration and stem-cell mobilization, and both converge on the neoangiogenesis required for deep tissue regeneration. This combo is intended exclusively for RUO preclinical research and documented equine veterinary protocols (notably digital flexor tendon regeneration, well characterized in equine sports medicine).

Lot certified by HPLC certificate of analysis exceeding 99%, mass spectrometry confirming theoretical molecular weight (BPC-157: 1419.53 Da / TB-500 fragment: supplier-dependent, full thymosin beta-4: 4963 Da), cold chain maintained from synthesis to delivery. Unique dual-lyophilized vial, two-minute reconstitution, aliquoting supported to extend functional shelf life.

Science

01
Mechanism of action

BPC-157 — Cytoprotective pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val)

BPC-157 is a 15-amino-acid fragment of a larger 40 kDa protein isolated from human gastric juice. Its exceptional stability (acid-pH resistance, enzymatic resistance outperforming most bioactive peptides) enables partial oral bioavailability and a systemic half-life compatible with once-daily administration. Four mechanisms are established by over 500 peer-reviewed publications from the Zagreb school (Sikiric, Seiwerth, Staresinic, Krivic) and independent laboratories:

1. VEGF-R2 axis / local angiogenesis — BPC-157 upregulates VEGF-R2 (KDR) receptor expression on vascular endothelium at the lesion site, triggering early neoangiogenesis required for tendon and ligament repair (Sikiric 2018, successive reviews).
2. FAK-paxillin signaling in tendon fibroblasts — Chang et al. (J Appl Physiol 2011) showed BPC-157 accelerates tendon fibroblast migration in vitro via FAK and paxillin phosphorylation, a critical pathway in focal adhesion remodeling.
3. NO / eNOS axis modulation — BPC-157 normalizes nitric oxide production, a vascular and mucosal protective effect demonstrated in ischemia-reperfusion and gastroduodenal injury models.
4. Growth hormone receptor upregulation — GH-R expression on tendon fibroblasts is increased, potentiating the local anabolic response to circulating IGF-1.

TB-500 — Thymosin beta-4 fragment (44 aa, Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES)

Thymosin beta-4 is the most abundant member of the beta-thymosin family in mammalian cell cytoplasm. Its primary function is G-actin sequestration — TB4 binds monomeric actin with nanomolar affinity, regulates the polymerizable actin pool, and indirectly governs cytoskeletal dynamics during cell migration, wound healing and inflammatory response. Five mechanistic axes are documented:

1. G-actin sequestration — Primary function, essential for motility of fibroblasts, keratinocytes, endothelial cells and cardiomyocytes.
2. Angiogenic AcSDKP generation — Prolyl oligopeptidase cleaves TB4 and releases the tetrapeptide Ac-Ser-Asp-Lys-Pro, an autonomous angiogenic factor layered on top of TB4's direct effect on endothelial migration.
3. Laminin-5 and MMP upregulation — TB4 induces expression of matrix metalloproteinases (MMP-2, MMP-9) that remodel extracellular matrix during healing (Malinda 1999 J Invest Dermatol).
4. Mesenchymal progenitor cell mobilization — TB4 activates cardiac epicardial progenitors (Smart 2011 Nature) and mobilizes hair follicle cutaneous stem cells.
5. Anti-inflammation — NF-kB pathway inhibition and reduced pro-inflammatory mediator production in keratitis and colitis models.

Combo synergy — Vascular convergence, tissue divergence

Complementarity hinges on a single principle: BPC-157 initiates local repair, TB-500 amplifies systemic regeneration. On angiogenesis, both peptides converge (VEGF-R2 for BPC-157, AcSDKP for TB-500) and potentiate each other — the shared denominator. On matrix remodeling they diverge: BPC-157 acts specifically on tendon fibroblast signaling, TB-500 acts transversally across all repairing tissues via actin dynamics. On the hormonal axis, BPC-157 potentiates local IGF-1 while TB-500 mobilizes stem cells — two orthogonal anabolic levers.

Clinical data

02Clinical studies

BPC-157 peer-reviewed corpus — Zagreb school and associated laboratories

The BPC-157 corpus exceeds 500 indexed publications since the 1990s, predominantly from the Pharmacology Laboratory at Zagreb Faculty of Medicine (Predrag Sikiric, Sven Seiwerth, Mario Staresinic, Tomislav Krivic, Rudolf Pevec). Foundational work established gastroduodenal cytoprotection (Sikiric 1993 onward), then extended to intestinal ischemia-reperfusion, tendon, ligament, muscle and cardiac injury models.

- Staresinic et al. (J Orthop Res 2003) — Transverse medial collateral ligament injury in rat; systemically administered BPC-157 accelerated histological repair and biomechanical recovery.
- Krivic et al. (2008) — Achilles tendon rupture in rat; BPC-157 improved tensile failure load and collagen fiber density at 14 days post-injury.
- Pevec et al. (2010) — Crush muscle injury in rat; accelerated muscle regeneration with oral or intraperitoneal BPC-157.
- Chang et al. (J Appl Physiol 2011) — Human tendon fibroblasts in vitro; BPC-157 accelerated migration and upregulated FAK-paxillin signaling.
- Seiwerth et al. (Current Pharm Des 2014) — Review compiling the mechanisms known at that date (VEGF-R2, NO, dopamine, serotonin, GH-R).
- Sikiric et al. (Current Neuropharm 2016, Current Med Chem 2018) — Extended reviews including the gut-brain axis, vascular repair and neuroprotection.

The absence of any large-scale randomized placebo-controlled human trial to date is the major limitation: all evidence is preclinical (rodent) or in vitro. Observational human protocols reported in gray literature reflect uncontrolled RUO or veterinary use.

Thymosin beta-4 / TB-500 corpus

Thymosin beta-4 enjoys an older corpus (Goldstein 1981 PNAS discovery) and human clinical trials in ophthalmology, dermatology and cardiology.

- Goldstein et al. (PNAS 1981) — Initial isolation from bovine thymus, 44-aa sequence determined.
- Malinda et al. (J Invest Dermatol 1999) — Cutaneous wound-healing model in rat; TB4 accelerated wound closure, induced laminin-5 and MMPs, stimulated keratinocyte migration.
- Sosne et al. (Exp Eye Res 2005) — Topical TB4 in keratitis; accelerated corneal re-epithelialization, phase II corneal ulceration trials (RegeneRx).
- Kim et al. (J Mol Cell Cardiol 2003) — Cardiac protection post-ischemia in mouse.
- Smart et al. (Nature 2011) — TB4 activation of cardiac epicardial progenitors post-infarct, myocardial regeneration.
- Crockford et al. (Ann NY Acad Sci 2010) — Phase II clinical trial of TB4 in acute myocardial infarction (RegeneRx).
- Philp and Kleinman (Ann NY Acad Sci 2010) — Review of regenerative applications (cornea, skin, cardiac, cerebral ischemia).

Critical note: the product marketed as "TB-500" in the research peptide supply chain corresponds either to full-length thymosin beta-4 (44 aa) or to an N-terminal fragment concentrated on AcSDKP, depending on supplier. The HPLC certificate of analysis and molecular weight measured by mass spectrometry are the decisive criteria. Our lots explicitly declare the supplied molecule on the CoA.

No references yet for this peptide — search PubMed for associated scientific literature.

The listed studies are provided for documentation and research purposes only. They do not constitute a therapeutic indication nor a recommendation for human use. This product is strictly for laboratory use only (RUO).

Lab workflow

03
Research protocols

Reconstituting the 10mg combo (BPC-157 5mg + TB-500 5mg)

The dual-lyophilized vial contains 10 mg total peptide (5 mg of each). Standard reconstitution:

- Draw 2 ml of bacteriostatic water (benzyl alcohol 0.9% or 1%) into a 3 ml syringe with a 21G needle;
- Disinfect the combo vial septum with an isopropyl wipe, let it dry for 10 seconds;
- Inject the water slowly along the inner wall of the vial (never inject directly onto the lyophilized powder — mechanical impact denaturation risk);
- Withdraw the syringe, roll the vial gently between your palms (never shake vigorously — disulfide bonds and tertiary structure are impact-sensitive);
- Wait 60 to 120 seconds for full dissolution and a clear solution.

Final concentration: 2.5 mg/ml of each peptide (5 mg/ml total peptide), which on a 1 ml insulin syringe graduated to 100 IU translates as:
- 10 IU = 0.1 ml = 250 mcg BPC-157 + 250 mcg TB-500
- 20 IU = 0.2 ml = 500 mcg BPC-157 + 500 mcg TB-500
- 40 IU = 0.4 ml = 1 mg BPC-157 + 1 mg TB-500

Reference protocols in preclinical research and RUO veterinary use

Two schemes dominate the gray literature and equine veterinary protocols:

- Loading phase — 4 to 6 weeks: 500 mcg BPC-157 + 500 mcg TB-500 per day, one subcutaneous injection daily. Injection site adjacent to the lesion for BPC-157 (local cytoprotection rationale), indifferent site for TB-500 (systemic action). Practical option: combined subcutaneous abdominal injection when the lesion is not accessible.
- Maintenance phase — 4 to 8 weeks post-loading: 500 mcg combined 2 to 3 times per week; objective is consolidation of matrix remodeling and newly formed vascularization.

Routes of administration

- Subcutaneous (SC) — Standard route, peri-umbilical adipose tissue. Rotate sites every 7 to 10 days to prevent local lipodystrophy.
- Peri-lesional intramuscular (IM) — Documented in equine veterinary practice for tendinopathies (superficial digital flexor tendon); peptide is deposited in immediate proximity to the lesion.
- Topical / intralesional — Rare, reserved for dermatological wound-healing protocols (TB-500).

Cycles and washouts

Typical full cycle duration: 8 to 14 weeks, followed by a 4 to 8 week washout. Washouts allow reassessment of clinical recovery (veterinary) or histological recovery (preclinical) before any reintroduction. No robust data documents uninterrupted chronic use beyond 6 months.

Reconstitution for this format (10 mg)Standard volumes used in laboratory settings

Water added	Concentration	Reading marker
1 ml	10 mg/ml	10 UI = 1 mg
2 ml	5 mg/ml	40 UI = 2 mg

The volume of water does not change the product, only its concentration. Introduce the water slowly along the vial wall, never directly onto the lyophilisate, then swirl without shaking. Markers given on a 1 ml syringe graduated in 100 units.

Asepsis

Disinfect surfaces and stoppers (70% alcohol).

Solvent

Draw the required volume of bacteriostatic water.

Introduction

Inject gently against the vial wall (avoid direct jet on powder).

Solubilization

Roll the vial gently. Do not shake vigorously (degradation risk).

Solution storageOnce reconstituted: 2-8°C (refrigerator).

WarningTheoretical tool for chemical handling. Does not constitute medical advice.

I open the dilution calculator

What is normal on arrivalThe observations that worry customers, and are not defects

The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
The vial carries no individual label. That is our standard packaging, not a downgraded vial.
After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
The parcel is plain. Nothing on the outside indicates the contents or the brand name.

What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.

Handling

04Storage & handling

Storage before reconstitution (lyophilized)

The sealed lyophilized combo vial must be stored between +2 and +8 C (refrigerator) in its original packaging, protected from light. Under these conditions, stability exceeds 24 documented months for BPC-157 and thymosin beta-4. Transit tolerates up to 48 hours at room temperature (<25 C) without significant degradation, but prolonged room-temperature storage is to be avoided.

For very long-term storage (>12 months pre-reconstitution), an intact lyophilized vial can be stored at -20 C (standard freezer). Always avoid freeze-thaw cycles.

Storage after reconstitution

Once reconstituted with bacteriostatic water:

- BPC-157 alone solution: confirmed stability 14 to 21 days at +4 C (refrigerator).
- TB-500 alone solution: confirmed stability 21 to 28 days at +4 C.
- Combo reconstituted solution: use within 14 days (combo stability is governed by the less stable peptide, BPC-157).

Always store the reconstituted vial in its original box or in an opaque container to protect from UV light. Visually inspect before every use: the solution must remain clear, colorless to faintly straw-yellow, particle-free and non-turbid. Any cloudiness, precipitation or color shift (dark yellow, brown) requires immediate disposal of the vial.

Aliquoting (recommended for protocols > 21 days)

To preserve peptide potency by extending functional shelf life, aliquoting into sterile micro-tubes and storage at -20 C is the reference practice:

- Reconstitute the full vial, draw 0.2 ml to 0.4 ml aliquots (sufficient for 1 to 2 injections) into sterile Eppendorf tubes;
- Store at -20 C for up to 6 months (preclinical literature documents >90% HPLC recovery post-thaw);
- Thaw one aliquot overnight at 4 C, return to room temperature just before injection;
- Never re-freeze a thawed aliquot.

Shipping and cold chain

Delivery in insulated pack with cold gel, 24/48 h tracked transit. Upon receipt, place immediately in refrigerator. If the package arrives at room temperature after > 72 h transit, contact customer service before use.

01What is the reference combo dose in preclinical research?

The scheme most frequently reported in gray literature and equine veterinary protocols is **500 mcg BPC-157 + 500 mcg TB-500 per day subcutaneously** for 4 to 6 weeks (loading phase), followed by 500 mcg combined 2 to 3 times per week for 4 to 8 weeks (maintenance). Some preclinical rodent studies use weight-normalized doses (10 mcg/kg BPC-157). No human dose has been validated by clinical trial: strictly RUO use.

02Are BPC-157 and TB-500 compatible in the same vial?

Yes. Both peptides are chemically stable side by side in bacteriostatic aqueous solution, with different isoelectric points (BPC-157 pI ~5.5; TB4 pI ~4.8) but no documented peptide-peptide interaction. The dual co-lyophilizate certified by a common CoA ensures homogeneity. Reconstituted combo stability is governed by the less stable peptide (BPC-157, 14 days at +4 C).

03Should BPC-157 be injected near the lesion and TB-500 distally?

In theory yes: BPC-157 follows a local cytoprotection logic (VEGF-R2, FAK-paxillin) that favors peri-lesional injection when the area is accessible, while TB-500 acts systemically and can be injected at an indifferent site (abdomen). In practice with a reconstituted combo, both peptides are co-injected and the theoretical benefit of separate administration has not been demonstrated by comparative data. The equine veterinary consensus is **single peri-tendinous injection** to simplify the protocol.

04Can the combo be stacked with other peptides (IGF-1, GHK-Cu, CJC/Ipamorelin)?

In preclinical research, BPC-157+TB-500 stacks with a growth hormone secretagogue (CJC-1295 + Ipamorelin) or with GHK-Cu (for skin) are documented in gray literature. Mechanisms are orthogonal: no known pharmacokinetic interaction, expected anabolic potentiation via the IGF-1 axis. These combinations remain RUO and are not supported by any comparative human clinical trial.

05How long does a full cycle last and what washout should be respected?

A typical cycle lasts **8 to 14 weeks** (4 to 6 weeks loading + 4 to 8 weeks maintenance), followed by a **4 to 8 week washout**. The washout allows assessment of histological (preclinical) or clinical (veterinary) recovery before any reintroduction. No robust data documents safety of uninterrupted chronic use beyond 6 months.

06What is the difference between TB-500 and full thymosin beta-4?

**Thymosin beta-4** (TB4) is the complete endogenous 44-residue molecule. **"TB-500"** as marketed in the research peptide supply chain refers, depending on supplier, either to full TB4 or to an N-terminal fragment concentrated on the active AcSDKP sequence (angiogenic tetrapeptide). Only the lot's HPLC CoA + mass spectrometry resolves the ambiguity. Our vials explicitly declare the supplied molecule on the certificate.

07Is this combo usable in equine veterinary medicine?

Yes, this is in fact the best-documented use context outside of preclinical rodent research. **Superficial digital flexor tendon tendinopathies** in racehorses are the subject of reported observational veterinary protocols. Use remains under the responsibility of the attending veterinarian, within the regulatory framework applicable to research peptides (RUO) and veterinary medicinal products in the relevant jurisdiction.

08What are the known contraindications and warning signs?

No randomized human clinical trial has characterized contraindications. In preclinical and veterinary settings, theoretical alerts concern: (1) **history of active cancer**, particularly vascularized solid tumors, because the angiogenic effects of BPC-157 (VEGF-R2) and TB-500 (AcSDKP) could theoretically favor tumor vascularization; (2) **pregnancy and breastfeeding** — no data, to be avoided; (3) **proliferative retinopathies** — neoangiogenesis could worsen disease. In research, any observation of abnormal bleeding, abdominal pain, cutaneous lesion change or unusual symptom should prompt discontinuation and medical evaluation.

Benchmark

Similar peptides

Combo versus BPC-157 alone

BPC-157 alone remains the reference cytoprotective peptide for gastroduodenal protocols, ischemia-reperfusion models and local tendon repair. The combo adds the systemic dimension of thymosin beta-4: progenitor cell mobilization, generalized actin remodeling, AcSDKP angiogenic activity. For deep, multi-tissue tendon or ligament injuries, the combo covers a broader tissue spectrum than BPC-157 in isolation.

Combo versus TB-500 alone

TB-500 alone excels on cutaneous wounds, corneal regeneration and cardiac protection models. The combo adds gastrointestinal cytoprotection, fibroblast-specific FAK-paxillin signaling in tendons, and local IGF-1 / GH-R axis potentiation. On pure tendinopathies, the combo outperforms TB-500 alone in the majority of documented equine veterinary protocols.

Combo versus GHK-Cu

GHK-Cu (copper tripeptide) is oriented toward cutaneous wound healing and cosmetics, with a strong axis on dermal collagen synthesis and anti-glycation. The BPC-157+TB-500 combo is oriented toward deep tendon, ligament and visceral regeneration. The two are complementary and non-redundant: GHK-Cu for dermis and adnexae, BPC-157+TB-500 for deep structures (tendons, ligaments, muscles, gut).

Combo versus hyaluronic acid or PRP injections

Intra-articular hyaluronic acid injections deliver passive lubrication with no structural regenerative effect. PRP (platelet-rich plasma) provides a heterogeneous cocktail of autologous growth factors (PDGF, TGF-beta, IGF-1), but its composition varies from one draw to another. The BPC-157+TB-500 combo offers a defined, dosable, lot-to-lot reproducible peptide composition via HPLC CoA, with characterized mechanisms of action. By contrast, PRP and HA benefit from randomized human clinical data (knee osteoarthritis, tendinopathies) that the combo lacks.

Combo versus conventional pharmacology

NSAIDs (ibuprofen, diclofenac) reduce acute pain and inflammation but delay tissue repair by blocking the constructive inflammatory phase. Infiltrated corticosteroids relieve pain but accelerate long-term tendon degeneration. The BPC-157+TB-500 combo positions itself as a pro-regenerative strategy orthogonal to symptomatic anti-inflammatories, with an opposite mechanistic logic.

Regeneration

Asepsis

Solvent

Introduction

Solubilization

Complementary reagents